Eli Lilly (LLY) P/E ratio
Eli Lilly (LLY) trades at 46.0× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 46.8×. That is 29.0% lower than the 65.9× of fiscal 2024. Figures as of 17 Nov 2026, 17:18 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio today
- 46.0×
- P/E ratio, fiscal 2025
- 46.8×
- Change on fiscal 2024
- −29.0%
- Highest on record
- 100.5×fiscal 2023
- Lowest on record
- 7.7×fiscal 2010
- Fiscal years on record
- 162009–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Eli Lilly P/E ratio, in more detail
Today's figure is 1.8% below the fiscal 2025 year-end.
Across the 16 fiscal year-ends on record (2009–2025), the highest was 100.5× in fiscal 2023 and the lowest 7.7× in fiscal 2010. Today's P/E ratio is higher than at 75% of the 16 fiscal year-ends on record; their median is 29.7×.
P/E ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Eli Lilly P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| Today | 46.0× | — | $1,416.47 | — | |
| 2025 | 46.8× | 29.0% down | $1,074.68 | $22.95 | |
| 2024 | 65.9× | 34.4% down | $772.00 | $11.71 | |
| 2023 | 100.5× | 80.6% up | $582.92 | $5.80 | |
| 2022 | 55.7× | 23.3% up | $365.84 | $6.57 | |
| 2021 | 45.1× | 81.5% up | $276.22 | $6.12 | |
| 2020 | 24.9× | 68.2% up | $168.84 | $6.79 | |
| 2019 | 14.8× | 60.0% down | $131.43 | $8.89 | |
| 2018 | 37.0× | — | $115.72 | $3.13 | |
| 2017 | — | — | $84.46 | -$0.19 | |
| 2016 | 28.5× | 23.5% down | $73.55 | $2.58 | |
| 2015 | 37.3× | 20.5% up | $84.26 | $2.26 | |
| 2014 | 30.9× | 162.1% up | $68.99 | $2.23 | |
| 2013 | 11.8× | 12.4% down | $51.00 | $4.32 | |
| 2012 | 13.5× | 26.5% up | $49.32 | $3.66 | |
| 2011 | 10.7× | 39.3% up | $41.56 | $3.90 | |
| 2010 | 7.7× | 15.6% down | $35.04 | $4.58 | |
| 2009 | 9.1× | — | $35.71 | $3.94 | |
| 2008 | — | — | $40.27 | -$1.89 | |
| 2007 | — | — | $53.39 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
P/E ratio at health care companies of similar size
| Company | P/E ratio |
|---|---|
| Eli Lilly LLY | 46.0× |
| Johnson & Johnson JNJ | 42.6× |
| AbbVie ABBV | 50.5× |
| Merck & Co MRK | 145.5× |
| UnitedHealth Group UNH | 22.7× |
| Novartis NVS | 30.5× |
Price over the last twelve months' earnings per share, as the market data feed reports it.
Eli Lilly, figure by figure
- Eli Lilly market cap
- Eli Lilly revenue
- Eli Lilly earnings
- Eli Lilly earnings per share (EPS)
- Eli Lilly P/S ratio
- Eli Lilly P/B ratio
- Eli Lilly free cash flow
- Eli Lilly operating margin
- Eli Lilly dividend
- Eli Lilly shares outstanding
- Eli Lilly total debt
- Eli Lilly cash on hand
- Eli Lilly total assets
- Eli Lilly return on equity (ROE)
- Eli Lilly return on invested capital (ROIC)
Eli Lilly (LLY) overview: price, valuation and scorecardAll health care companies by market value
Eli Lilly P/E ratio: questions and answers
What is Eli Lilly's P/E ratio?
Eli Lilly (LLY) trades at 46.0× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 46.8×. That is 29.0% lower than the 65.9× of fiscal 2024.
Is Eli Lilly's P/E ratio high or low compared with its own history?
Today's P/E ratio is higher than at 75% of the 16 fiscal year-ends on record; their median is 29.7×.
What are the highest and lowest P/E ratio figures on record for Eli Lilly?
Across the 16 fiscal year-ends on record (2009–2025), the highest was 100.5× in fiscal 2023 and the lowest 7.7× in fiscal 2010.
How is Eli Lilly's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Eli Lilly (LLY) P/E ratio”, data as of 17 November 2026. https://funkfolio.com/stock/LLY/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.